My SciELO
Services on Demand
Article
Indicators
Cited by SciELO
Related links
Similars in SciELO
Share
Revista Habanera de Ciencias Médicas
On-line version ISSN 1729-519X
Abstract
HONG YING, Li et al. Evaluation of experimental immunotherapeutic formulations in the hybrid murine model of Graft-versus-Host Reaction. Rev haban cienc méd [online]. 2020, vol.19, n.1, pp. 10-29. Epub Feb 01, 2020. ISSN 1729-519X.
Introduction:
Graft-versus-host disease is the most frequent complication of Hematopoietic Stem Cell Transplants and all transplants containing allogeneic immunocompetent cells; 100% of patients suffer from this complication and about 30% die for this particular cause. A high proportion of cases are steroid-refractory; likewise, other modern immunosuppressive measures fail. In the fields of Immunotherapy and Vaccinology, there is also a worrying shortage of powerful, effective, safe and broad spectrum immunomodulators of biological origin. There is a hybrid murine model of great methodological utility for experimental studies.
Objective:
To evaluate two novel formulations of biotechnological origin: an immunopotentiator formulation and an immunosuppressive one, which were developed as cochleates.
Material and Methods:
The formulations assayed by Electron Microscopy and RT-PCR were characterized as nanoparticles and for their capacity to regulate lymphokine mRNA expression profile, respectively. The immunomodulatory character was evaluated in vivo using Graft-versus-host disease in (CBAxC57BL) F1 hybrid mice.
Results:
Starting from the proteoliposomes derived from Neisseria meningitides, two cochleate formulations were obtained, both with particle diameters below 100 nm. Formulation 1 showed a proinflammatory profile with potent capacity to increase IFNγ and TNFα, and potentiated the Spleen Index up to 2.05 in the GVDH model with p = 0.0002. Formulation 2 showed a suppressor/regulatory profile with potent capacity to increase IL-10 and TGFβ and suppress the production of TNFα. In the model used, this formulation suppressed the Spleen Index in a dose-dependent manner with high statistical significance. The known safety profile and absence of reactogenicity of both formulations was corroborated.
Conclusions:
Both formulations have potential application in the fields of GVHD therapy and other pathologies as well as in Vaccinology. The results obtained in the present work suggest the usefulness to continue with the pharmaceutical development and complete the preclinical studies of both formulations.
Keywords : Immunomodulators; Cochleate; Immunotherapy; Graft-Versus-Host Disease (GVHD); Murine model; Hematopoietic Stem Cell Transplants (HSCT); cytokines.